Overall, the results of this study highlight the benefit of brimarafenib and mirdametinib combination treatment in NRAS mutated melanoma models and provide supportive preclinical evidence for the investigation of this combination approach in melanoma patients harboring NRAS or other RAS‐mutations. This evidence concerns the gene NRAS and melanoma.